Target intelligence / Profile preview

Immunoglobulin heavy variable 2-70 (IGHV2-70)

Target
IGHV2-70
Molecular classification
Other (Immunoglobulin variable region), Antigen binding domain
01

Overview

Immunoglobulin heavy variable 2-70 is a protein-coding gene segment encoding the variable region of the heavy chain of immunoglobulins (antibodies)[2][5][6]. The variable region participates directly in antigen recognition, contributing to the remarkable diversity and specificity of the antibody repertoire generated by B lymphocytes. Each immunoglobulin molecule's antigen-binding site is composed of a variable domain from one heavy chain and its associated light chain. The sequence diversity is created through V-(D)-J recombination and further enhanced by somatic hypermutation, which together allow adaptation and maturation of the humoral immune response upon antigen exposure[2][6]. Polymorphism in IGHV genes, including IGHV2-70, underlies inter-individual variability in antibody-mediated responses to infectious agents, autoimmune diseases, vaccine outcomes, and B cell malignancies[3]. While not a classical drug target, IGHV2-70 is essential for immune diversity and is used as a molecular marker in certain research and diagnostic contexts[3][5][6].

Other names
IGHV2-70Ig heavy chain V-II region CORIg heavy chain V-II region DAWIg heavy chain V-II region OUIg heavy chain V-II region SESSIGHV270VHImmunoglobulin heavy chain variable region
02

Mechanism of action

null (No approved drugs act by binding this region as a direct pharmacological target; its function is to provide diversity to antibody recognition.)

03

Biological functions

Antigen bindingAdaptive immune responseHumoral immunity
04

Disease associations

Cancer (contributes to antibody diversity implicated in B cell malignancies)Infection (determines antibody-mediated protection against pathogens)Autoimmunity (variability influences autoantibody repertoires)Other (overall impact on immunological diversity and disease susceptibility)
05

Safety considerations

Polymorphism can affect immune responses to infection and vaccines [3]Somatic mutation or translocation of immunoglobulin loci can contribute to B cell malignancies (research context, not specific to IGHV2-70)
06

Biomarkers

IGHV gene family usage (sometimes used in the assessment of B cell malignancies, e.g., chronic lymphocytic leukemia) [3]Antibody repertoire profiling (research contexts)

Beyond the preview

Go deeper on Immunoglobulin heavy variable 2-70 (IGHV2-70).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy variable 2-70 (IGHV2-70).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call